Tenon Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-14. It has amended it 4 times. It filed its final prospectus on 2026-06-30. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “TNON.” The last reported sale price of our common stock on The Nasdaq Capital Market on June 29, 2026 was $0.4465 per share.From the 424B4 filed 2026-06-30
Shares offered
We are offering on a reasonable best efforts basis up to 5,526,315 shares of our common stock, par value $0.001 per share, together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the “Common Warrants”), at a combined public offering price of $0.38 per share of common stock and accompanying Common Warrants; provided however, if we effect a reverse stock split, the number of shares of common stock issuable under the Common Warrants will increase to 16,578,947 (on a pre-stock split basis).From the 424B4 filed 2026-06-30
Use of proceeds
We currently intend to use the net proceeds to us from this offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of our product portfolio including training clinicians on our current procedures, hiring additional direct sales reps, expansion of our external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.From the 424B4 filed 2026-06-30
Net loss or income
The decrease in net cash used in operating activities for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023 was primarily attributable to our decreased net loss of $1.7 million, adjusted for decreases in non-cash stock-based compensation expenses ($42), in addition to increased accounts payable ($316), partially offset by decreases in accrued expenses ($313).From the S-1/A filed 2024-11-04
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-14 | Registration statement filed | S-1 |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2024-09-16 | Final prospectus filed: the offering is priced | 424B4 |
| 2024-10-17 | Registration statement filed | S-1 |
| 2024-11-04 | Registration statement amended | S-1/A |
| 2025-04-04 | Registration statement filed | S-1 |
| 2026-06-22 | Registration statement filed | S-1 |
| 2026-06-26 | Registration statement amended | S-1/A |
| 2026-06-30 | Final prospectus filed: the offering is priced | 424B4 |
Tenon Medical, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Tenon Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.